[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"impaired-glucose-tolerance\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:impaired-glucose-tolerance":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,47,74,97,122,150],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100555102","night-owl-metabolism-100555102",false,"NCT06507722","Night Owl Metabolism","Night Owl Metabolism: Investigating the Impact of Chronotype on Glucose Metabolism in Youth","Inclusion Criteria:\n\n* Overweight similar to (BMI ≥ 85th percentile but \\\u003C95th percentile for age and sex per Centers for Disease Control and Prevention growth curves (as Centers for Disease Control and Prevention growth curves contain ages ≤ 20y; if ages 21-23 years, the BMI ≥ 85th and \\\u003C95th percentile equivalents for a 20-year-old will be used))\n* Post-pubertal\n* Normal sleep duration (avg. \\>7 hours of sleep per night)\n* Social jetlag (difference between weekend and weekday sleep) of \\\u003C 2 hours.\n\nExclusion Criteria:\n\n* Known diabetes, sleep disorders, major organ system illness, pregnancy, or genetic syndrome\n* Medication use known to affect insulin sensitivity, glucose tolerance, or circadian rhythm\n* Screening high risk for obstructive sleep apnea\n* Night shift work.",true,"ALL","18 Years","23 Years",{"count":21,"type":22},70,"ESTIMATED","INTERVENTIONAL",[25],"NA","The proposed study uses a novel and rigorous randomized cross-over study design in youth (18-23y) with late and non-late chronotype (n=35 per group) to assess the glycemic effect of \"aligning\" an oral glucose tolerance test (OGTT) or first-meal of day to a subject's chronotype. Both groups will undergo 2 OGTTs (aligned and mis-aligned with chronotype) to compare glucose tolerance and insulin sensitivity within-subject (primary outcome) and between groups (Aim 1). Then, youth will also undergo two standardized meals (aligned and mis-aligned with chronotype) while wearing continuous glucose monitoring to compare post-prandial glucose excursions within-subject and between groups (Aim 2). A pilot Exploratory Aim 3 (n=12 per group) will investigate delayed melatonin patterns under dim-light as a potential pathophysiologic mechanism behind abnormal glucose tolerance in youth with late chronotype on morning OGTTs.",[28,29,30],"PreDiabetes","Overweight","Impaired Glucose Tolerance",[32,33],"chronotype","sleep","RECRUITING","2026-05-07",{"date":37,"type":38},"2026-05-11","ACTUAL",{"date":40,"type":38},"2025-02-25",{"date":42,"type":22},"2030-01-31",{"name":44,"class":45},"Johns Hopkins University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":18,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":46},"100469034","cgm-and-lifestyle-changes-in-patients-with-impaired-glucose-tolerance-100469034","NCT05387551","CGM and Lifestyle Changes in Patients With Impaired Glucose Tolerance","Effect of Adding Continuous Glucose Monitoring (CGM) to Lifestyle Changes on Insulin Sensitivity in Patients With Impaired Glucose Tolerance","Inclusion Criteria:\n\n1. Children 10 to \\\u003C18 years old (i.e., before their 18th birthday)\n2. Impaired glucose tolerance based on standardized oral glucose tolerance test (OGTT) or fasting glucose per American Diabetes Association criteria,\n3. Overweight or obese (BMI ≥85th percentile for age\u002Fsex)\n4. Patients are pubertal, defined as females with breast Tanner stage II or above, or males with testicular volume ≥4 mL\n\nExclusion Criteria:\n\n1. Existing diagnosis of type 1 or type 2 diabetes\n2. Prepubertal\n3. Taking medications that affect insulin sensitivity (e.g.,chronic corticosteroids whether systemic or inhaled). Metformin allowed if stable dose.\n4. Patients and\u002For families not willing to wear the CGM for the duration of the study period or lack of compliance after recruitment","10 Years",{"count":56,"type":22},15,[25],"The incidence of type 2 diabetes (T2D) in children is increasing, paralleling the rising incidence of obesity. Preventing children and adolescents from developing T2D is critical. The health benefits of lifestyle modifications are well documented in this population, but success rates are low. Obesity in children and adolescents increases the risk of not only T2D but other complications as well, such as hypertension, dyslipidemias and more. The investigators hypothesize that having real-time glucose data with the use of a continuous glucose monitor (CGM) in obese patients with impaired glucose tolerance will improve adherence to lifestyle modifications. As a result, a decrease in body mass index (BMI) is expected with subsequent improvement in insulin sensitivity, thus reducing risk of obesity-related complications later in childhood\u002Fadolescence and adulthood.",[30,60],"Prediabetes",[62,63,64],"impaired glucose tolerance","obesity","adolescents","2025-11-20",{"date":67,"type":38},"2025-11-26",{"date":69,"type":38},"2022-12-01",{"date":71,"type":22},"2026-12",{"name":73,"class":45},"Nemours Children's Clinic",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":83,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":46},"100590223","early-phase-1-efficacy-and-safety-of-sanggua-tablets-in-the-treatment-of-patients-with-impaired-glucose-tolerance-and-mild-type-2-diabetes-100590223","NCT06964620","Efficacy and Safety of Sanggua Tablets in the Treatment of Patients With Impaired Glucose Tolerance and Mild Type 2 Diabetes","Inclusion Criteria:\n\n* Patients aged 18-70 with impaired glucose tolerance (IGT).\n* Patients aged 18-70 diagnosed with type 2 diabetes mellitus (T2DM) deemed by the clinician not requiring pharmacological intervention.\n* Glycated hemoglobin (HbA1c) levels between 5.6% and 7.5%.\n* Voluntarily sign an informed consent form before the commencement of trial-related activities, understand the procedures and methods of the trial, and are willing and able to strictly adhere to the clinical trial protocol to complete the study.\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus.\n* Known allergies to Sang Gua tablets or any of its components.\n* Use of hypoglycemic or lipid-lowering drugs within the last three months.\n* Presence of severe primary or secondary respiratory, cardiovascular, hepatic, or renal diseases, rheumatic connective tissue diseases, or hematological disorders.\n* Uncontrolled or unstable conditions exacerbated by infections, severe electrolyte imbalances, or other factors.\n* Patients with primary or secondary kidney diseases, hypertension, heart failure, acidosis, or urinary tract infections causing increased urinary protein, excepted.\n* Patients with psychiatric disorders.\n* Pregnant or planning to become pregnant women, or nursing mothers.\n* Patients requiring long-term steroid therapy.\n* Patients with poorly controlled hypertension or secondary hypertension.\n* Patients who have participated in other clinical trials within the past three months.\n* Patients deemed by the investigator as unsuitable for this clinical trial due to potential interference with trial results, impediments to full participation in the study, medical history, disease evidence, abnormal treatments, or laboratory values, or any other condition considered by the investigator to pose potential risks for participation in the study.","70 Years",{"count":82,"type":22},84,[84],"EARLY_PHASE1","Type 2 diabetes mellitus (T2DM) and impaired glucose tolerance (IGT) are growing public health challenges. Early intervention in mild T2DM and IGT is essential to prevent disease progression and severe complications. Traditional Chinese Medicine (TCM) provides a potential therapeutic approach.\n\nSanggua tablets, a TCM formula composed of mulberry leaf, bitter melon, kudzu root, Chinese yam, and cassia seed, embody TCM principles of clearing heat, generating body fluids, tonifying the spleen and stomach, and nourishing the lungs and kidneys. Modern studies show that Sanggua tablets effectively lower blood glucose and improve lipid profiles through components like mulberry polysaccharides and bitter melon saponins. These findings suggest their potential as an alternative or complementary therapy for mild T2DM and IGT.\n\nThis study will conduct a randomized, double-blind, placebo-controlled, parallel-group clinical trial among patients with IGT and mild T2DM. Participants will receive a 16-week intervention with Sanggua tablets. The primary outcome is glycated hemoglobin (HbA1c), with secondary outcomes such as fasting blood glucose (FBG), fasting insulin (FINS), HOMA-IR, lipid profiles and so on. Safety will be closely monitored. Additionally, fecal samples will be collected for 16S rDNA sequencing to explore the role of gut microbiota in the therapeutic effects of Sanggua tablets. This study aims to provide evidence for the clinical application and development of Sanggua tablets as a novel TCM therapy.",[87,30],"Diabetes Mellitus, Type 2","2025-05-15",{"date":90,"type":38},"2025-05-20",{"date":92,"type":22},"2025-05-22",{"date":94,"type":22},"2027-12-25",{"name":96,"class":45},"Tongji Hospital",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":103,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":107,"phases":4,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":46},"100506356","glucose-intolerance-and-diabetes-related-to-treatment-with-steroids-and-peg--asparaginase-in-children-and-adolescents-with-all-and-lymphoma-100506356","NCT05873322","Glucose Intolerance and Diabetes Related to Treatment With Steroids and PEG- Asparaginase in Children and Adolescents With ALL and Lymphoma","Inclusion Criteria:\n\n* All children and adolescents diagnosed with ALL and Lymphoma and treated according to the established and approved treatment protocols for these diseases in Denmark can be included in the study.\n\nExclusion Criteria:\n\n* Children and adolescents not fulfilling the inclusion criteria.","1 Year","17 Years",{"count":106,"type":22},100,"OBSERVATIONAL","The overall survival of acute lymphoblastic leukemia (ALL) and lymphoma in children and adolescents is above 90%. The survival rate has increased significantly during the last decades as a consequence of more intensive chemotherapy. This very toxic treatment results in severe acute toxicities and late effects, which is the biggest challenge today besides survival. The overall purpose of contemporary ALL treatment is to reduce the toxic treatment without compromising the excellent survival rates of these diseases. This study is a part of this. The researchers want to investigate the incidence of glucose intolerance and medicine induced diabetes during treatment for ALL and lymphoma with steroids (prednisolone or dexamethasone) and ± PEG-asparaginase.\n\nSteroids and asparaginase are used in the treatment of ALL and lymphomas, and both drugs may induce glucose intolerance or diabetes, especially when they are given concomitantly. The incidence and duration of increased blood glucose levels are not very well investigated, and especially not monitored continuously during treatment phases with steroids and +\u002F- asparaginase, as the investigators want to do in this study.\n\nIn the study the participants must have a glucose sensor attached under the skin, which continuously measures blood glucose during treatment. Moreover, blood samples are drawn several times to measure insulin sensitivity and beta cell function.\n\nThe participants are children and adolescents (1.0-17.9 years) with newly diagnosed ALL or lymphoma treated at one of the four Danish pediatric oncology sites.\n\nBlood glucose levels are followed during treatment with steroids and PEG-asparaginase in these patient groups. The results may give rise to a new treatment guidelines for measuring and treating blood glucose in these patients. In the future this may help reduce the development of type 2 diabetes mellitus and metabolic syndrome in survivors of ALL and lymphoma.",[110,111,30,112],"Precursor Cell Lymphoblastic Leukemia-Lymphoma","Drug-Induced Diabetes Mellitus","Lymphoma","2024-08-13",{"date":115,"type":38},"2024-08-14",{"date":117,"type":38},"2022-08-30",{"date":119,"type":22},"2025-12-31",{"name":121,"class":45},"Aarhus University Hospital",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":128,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":23,"phases":132,"briefSummary":133,"conditions":134,"keywords":135,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":4},"100554157","preliminary-safety-and-efficacy-study-of-extracellular-vesicle-infusion-in-the-intervention-of-age-related-phenotypes-with-impaired-glucose-tolerance-100554157","NCT06495437","Preliminary Safety and Efficacy Study of Extracellular Vesicle Infusion in the Intervention of Age-related Phenotypes With Impaired Glucose Tolerance.","Inclusion Criteria:\n\n1. The subjects are between 35 and 65 years old (inclusive), regardless of gender;\n2. The subject's body mass index (BMI) is between 20kg\u002Fm2 and 30 kg\u002Fm2;\n3. The subjects were assessed by the clinical expert group as having abnormal glucose tolerance (PPG 7.8-11.0mmol\u002FL 2h postprandial);\n4. Subjects voluntarily participate in this clinical study and sign a written informed consent.\n\nExclusion Criteria:\n\n1. The subject has a severe allergy or is allergic to any component used in cell culture;\n2. The subject has used or is using drugs that affect glucose metabolism (such as glucocorticoids, tricyclic antidepressants, etc.) within 1 month;\n3. The subjects have chronic diseases such as diabetes and hypertension (very high-risk group) which have not been effectively controlled after treatment;\n4. Subjects with severe cardiovascular and cerebrovascular diseases: patients with a history of decompensated cardiac insufficiency (NYHA grade Ⅲ or Ⅳ), myocardial infarction or cerebral infarction, or cerebral hemorrhage within 6 months before screening;\n5. The subjects had abnormal liver function (ALT and\u002For AST≥ 2.5 times the upper limit of normal), significant abnormal renal function, male serum creatinine ≥1.5mg\u002Fdl, female serum creatinine ≥1.4mg\u002Fdl; 6, the subject's HIV antibody, hepatitis B surface antigen, hepatitis C antibody, syphilis test positive, hepatitis B virus DNA quantitative \\> the upper limit of normal test unit;\n\n7\\. Subjects with other serious systemic diseases affecting the study, including malignant tumors, nervous central system, blood system, digestive system, endocrine system, respiratory system, infectious diseases, etc.; (8) Drug or alcohol abuse (subjects who consumed \\>2 alcoholic beverages per day or \\>14 alcoholic beverages per week (one alcoholic beverage is defined as 150ml of wine, 350ml of beer, or 50ml of 80% (40 proof) spirits); Or drug abusers; 9. Pregnant and lactating women; Have a pregnancy plan in the next 2 years (including the spouse's pregnancy plan); Refusal to use effective contraception; 10. Exclude intracranial lesions and early lung tumors; 11. Used stem cell (exosome) therapy or participated in stem cell (exosome) clinical researchers 3 months before screening; Clinical investigators who have participated in drugs within 3 months before screening; 12. High risk groups with Padua score ≥4 or Caprini score ≥5; 13. The subject has a history of major surgery within the past six months or is expected to have surgery within six months; 14. There are other conditions that the researcher considers inappropriate to participate in this clinical study.","35 Years","65 Years",{"count":131,"type":22},20,[25],"The objective of this exploratory study was to evaluate the initial safety of human mesenchymal stem cell-derived extracellular vesicle infusion in an age-related phenotype with impaired glucose tolerance",[30],[136,137,138,62],"Extracellular Vesicle","Aging","Human Mesenchymal Stem Cells","NOT_YET_RECRUITING","2024-07-17",{"date":142,"type":38},"2024-07-19",{"date":144,"type":22},"2024-08-01",{"date":146,"type":22},"2026-12-31",{"name":148,"class":149},"BEAUTECH","INDUSTRY",{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":156,"enrollmentInfo":157,"targetDuration":4,"studyType":23,"phases":159,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":46},"100509355","the-effects-of-an-obesogenic-lifestyle-in-recreationally-active-young-adults-100509355","NCT05912348","The Effects of an Obesogenic Lifestyle in Recreationally Active, Young Adults","Inclusion Criteria:\n\n* 18-30 years of age\n* Recreationally active completing 75-150 minutes of moderate-to-vigorous intensity exercise (\\>2 days\u002Fweek).\n* Fair cardiorespiratory fitness levels (Men: VO2\\>38.4 ml\u002Fkg\u002Fmin; Women: VO2\\>32.6 ml\u002Fkg\u002Fmin).\n\nExclusion Criteria:\n\n* Hypertension (resting or diagnosed)\n* Impaired fasting blood glucose (\\>100mg\u002FdL)\n* Diagnosed cardiovascular disease\n* Diagnosed diabetes\n* Diagnosed cancer\n* Diagnosed chronic kidney disease\n* Diagnosed musculoskeletal disorders that prevents the individual from exercising on a bike.","30 Years",{"count":158,"type":22},45,[25],"This clinical trial aims to learn about the alterations in insulin resistance and metabolic flexibility following a transition to an obesogenic lifestyle in fit young men and women. The main questions it aims to answer are:\n\n1. Does adding excess carbohydrates when transitioning to a sedentary lifestyle promote insulin resistance and impaired 24hr glucose regulation in healthy men and women?\n2. Does adding excess carbohydrates when transitioning to a sedentary lifestyle lower the body's ability to break down fats and carbohydrates in healthy men and women?\n3. Does the added physical activity blunt shifts in carbohydrate and fat oxidation in healthy men and women?",[162,30,163,164],"Insulin Resistance","Obesity","Metabolic Disturbance","2024-07-16",{"date":140,"type":38},{"date":168,"type":38},"2023-02-08",{"date":170,"type":22},"2026-09-30",{"name":172,"class":45},"University of New Hampshire"]